Table 7 Increase in the relative frequency (%), relative to placebo, in different outcomes, the corresponding number needed to treat (NNT) and 95% CIs calculated using a normal approximation. - Data were not available. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil
From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019
Outcome | PASI50 | PASI75 | PASI90 | |||
|---|---|---|---|---|---|---|
Follow-up time (weeks) | ||||||
24 | 24 | 24 | ||||
Drug | % | NNT (95% CI) | % | NNT (95% CI) | % | NNT (95% CI) |
Infliximab [195] | 66.7 | 1.5 (1.3–1.8) | 58.8 | 1.7 (1.4–2.1) | 38.4 | 2.6 (2.0–3.6) |
27.0 | 3.7 (2.6–6.3) | 20.8 | 4.8 (3.5–7.8) | – | – | |
Adalimumab [198] | 62.5 | 1.5 (1.2–1.8) | 58.8 | 1.7 (1.4–2.2) | 41.7 | 2.4 (1.9–3.3) |
Golimumab [199] | 66.7 | 1.5 (1.3–1.8) | 55.5 | 1.8 (1.6–2.2) | 32.2 | 3.1 (2.4–4.3) |
Certolizumab pegol [200] | 45.5 | 2.2 (1.7–2.9) | 45.5 | 2.2 (1.8–2.8) | 35.7 | 2.8 (2.2–3.7) |
– | – | 37.0 | 2.1 (1.8–2.6) | 35.7 | 2.7 (2.2–3.4) | |